Feedback / Questions
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
https://ir.adctherapeutics.com/press-releases/press-release-details/2022/ADC-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates/default.aspx
Nov 8, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next